Akeso (FRA:4RY) Inventories, Raw Materials & Components: €55.9 Mil (As of Dec. 2025)


FRA:4RY Akeso Inc FRA:4RY
54 GF Score
Price €9.19
GF Value €15.78
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Akeso Inventories, Raw Materials & Components?

Akeso FRA:4RY -4.29% 54 Inventories, Raw Materials & Components is €55.9 Mil as of Dec. 2025. GuruFocus rates FRA:4RY with a GF Score™ of 54/100 and a GF Value™ of €15.78 (Possible Value Trap). The stock has 5 warning signs investors should review.

Akeso's inventories, raw materials & components for the quarter that ended in Dec. 2025 was €55.9 Mil.

Akeso's quarterly raw materials declined from Dec. 2024 (€40.2 Mil) to Jun. 2025 (€0.0 Mil) but then increased from Jun. 2025 (€0.0 Mil) to Dec. 2025 (€55.9 Mil).

Akeso's annual raw materials increased from Dec. 2023 (€27.5 Mil) to Dec. 2024 (€40.2 Mil) and increased from Dec. 2024 (€40.2 Mil) to Dec. 2025 (€55.9 Mil).

Akeso Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Akeso's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akeso Inventories, Raw Materials & Components Chart

Akeso Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial 22.91 23.22 27.54 40.23 55.87

Akeso Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.54 0.00 40.23 0.00 55.87
FRA:4RY
54GF Score
Akeso Inc FRA:4RY
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akeso Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of €55.9 Mil mean?
Akeso (FRA:4RY) has a Inventories, Raw Materials & Components of €55.9 Mil as of Dec. 2025. Raw materials are the components a company uses for its main products. View historical data on Akeso and its competitors.
Is Akeso's Inventories, Raw Materials & Components too high?
Akeso's current Inventories, Raw Materials & Components is €55.9 Mil. Overall, Akeso has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Akeso's Inventories, Raw Materials & Components compare to VRTX and REGN?
Akeso's Inventories, Raw Materials & Components of €55.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Akeso and its competitors. Akeso's current Inventories, Raw Materials & Components is €55.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akeso stock overvalued right now?
Based on GuruFocus' analysis, Akeso (FRA:4RY) is currently considered Possible Value Trap. The stock's GF Value™ is €15.78, compared to a current price of €9.19 — trading 41.8% below its estimated fair value. The current Inventories, Raw Materials & Components is €55.9 Mil. Akeso's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Akeso (FRA:4RY), the current Inventories, Raw Materials & Components is €55.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akeso (FRA:4RY) Overvalued in 2026?

Based on GuruFocus' analysis, Akeso stock appears to be undervalued. The current stock price of €9.19 is trading 41.8% below its estimated GF Value™ of €15.78. GuruFocus considers Akeso to be Possible Value Trap.

Key valuation signals for FRA:4RY:

  • Inventories, Raw Materials & Components: €55.9 Mil
  • GF Value™: €15.78 vs. price of €9.19 (41.8% below fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the FRA:4RY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Akeso Business Description

Address No. 6, Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company has developed more than 50 drug candidates, including 15 bispecific antibody/multispecific antibody/bispecific antibody ADC/ADC/TCE drugs, with 27 drugs in clinical development. The majority of the company's revenue is derived from Mainland China, and it also has its presence in the USA and Other regions.
54GF Score

Get the complete analysis for FRA:4RY

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.19
Price
€15.78
GF Value